402616-23-3

Usage

Uses

Used in Pharmaceutical Industry:
FTY720 (R)-Phosphate is used as an immunomodulatory agent for the treatment of autoimmune diseases, particularly multiple sclerosis. It modulates the immune system by sequestering lymphocytes in the lymph nodes, reducing their migration to the central nervous system, and thereby mitigating the inflammatory process associated with the disease.
Used in Autoimmune Disease Treatment:
FTY720 (R)-Phosphate is used as a therapeutic agent for the treatment of autoimmune diseases. It targets the S1P receptors, which play a significant role in immune cell trafficking and function. By acting as an agonist at these receptors, FTY720 (R)-Phosphate can help regulate the immune response and reduce the severity of autoimmune conditions.
Used in Sphingolipid Homeostasis Research:
FTY720 (R)-Phosphate is used as a research tool in the study of sphingolipid homeostasis. As an intermediate in the sphingolipid pathway, it helps researchers understand the role of S1P receptors in various biological processes and their potential as therapeutic targets for immune system modulation.
Used in Drug Development:
FTY720 (R)-Phosphate serves as a starting point for the development of new drugs targeting the S1P receptors. Its unique mechanism of action and potential applications in autoimmune disease treatment make it an attractive candidate for further research and development in the pharmaceutical industry.

Upstream product

• 847672-62-2 (R/S)-4-[2-(4-octylphenyl)ethyl]-4-(3-oxo-1,5-dihydro-3λ⁵-benzo[e][1,3,2]dioxaphosphepin-3-yloxymethyl)oxazolidin-2-one 
• 402616-41-5 2-(benzyloxycarbonyl)amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol 
• 183129-84-2 4-(4'-n-octylphenyl)butan-1-ol 
• 13423-48-8 triphenylheptylphosphonium bromide 
• 876391-72-9 (2S)-2-(2'-(trichloromethyl)-4',5'-dihydrooxazol-5-yl)-4-(4''-octylphenyl)-butan-1-ol 
• 876391-70-7 (2S)-2-(oxiranyl)-4-(4'-octylphenyl)butan-1-ol 
• 876391-69-4 2-methylene-4-(4'-octylphenyl)butan-1-ol 
• 876391-68-3 2-methylene-4-(4'-octylphenyl)butanal 
• 876391-67-2 ((E)-4-Oct-1-enyl)-benzaldehyde 
• 162359-55-9 fingolimod 
• 863225-37-0 (R)-4-[2-(4-octylphenyl)ethyl]-4-(3-oxo-1,5-dihydro-3λ⁵-benzo[e][1,3,2]dioxaphosphepin-3-yloxymethyl)oxazolidin-2-one 
• 847672-61-1 (R/S)-4-hydroxymethyl-4-[2-(4-octylphenyl)ethyl]oxazolidin-2-one 
• 876391-73-0 phosphoric acid di-tert-butyl ester 4-[2-(4-octyl-phenyl)-ethyl]-2-trichloromethyl-4,5-dihydro-oxazol-4-ylmethyl ester 

Relevant academic research and scientific papers

Enantioselective synthesis of the phosphate esters of the immunosuppressive lipid FTY720

The enantiomers of FTY720-phosphate (3) were synthesized via 2-methylene-4-(4-octylphenyl)butan-1-ol (7), 2,3-epoxy alcohol 8, and Δ2-oxazoline 10. These compounds have potential use in the treatment of autoimmune diseases and prevention of kid

Asymmetric synthesis and biological evaluation of the enantiomeric isomers of the immunosuppressive FTY720-phosphate

A practical asymmetric synthesis of both enantiomers of the immunosuppressive FTY720-phosphate (2) was accomplished, and the enantiomers were pharmacologically evaluated. Several lipases showed considerable activity and enantioselectivity for O-acylation

Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer

In vivo phosphorylation of FTY720 (1) in rats and humans resulted exclusively in the biologically active (S)-configured enantiomer, which was proven by an ex vivo o-phthaldialdehyde derivatization protocol especially elaborated for phosphates of 1. Starting from the prochiral amino alcohol 1, racemic and enantiomerically pure phosphates of 1 were synthesized. Pure enantiomers were obtained after purification of a partially protected key intermediate on an enantioselective support. The absolute stereochemistry was determined by X-ray diffraction.

Synthesis, stereochemical determination and biochemical characterization of the enantiomeric phosphate esters of the novel immunosuppressive agent FTY720

The novel immunosuppressive agent FTY720 (1) is phosphorylated in vivo in a variety of species yielding an active metabolite that is an agonist of four of the five known G-protein-coupled sphingosine-1-phosphate (S1P) receptors. A synthesis amenable to pr